Eli Lilly and Company Faces 340B Lawsuit: Implications for Drug Pricing

Tampa General Hospital has filed a lawsuit against Eli Lilly and Company, alleging that the pharmaceutical company improperly withdrew 340B drug discounts. According to a report from Healthcare Finance News, Lilly terminated discounted pricing for Tampa General because the hospital failed to submit mandated information to a data platform.

This legal action highlights ongoing tensions between drug manufacturers and healthcare providers over the 340B Drug Pricing Program, which requires companies to offer outpatient drugs at reduced prices to qualifying hospitals that serve low-income and uninsured patients. Tampa General claims Lilly’s action violates federal law.

The lawsuit underscores the growing friction in the 340B program, as drugmakers increasingly impose data-sharing requirements on hospitals. For Eli Lilly, the case adds legal and regulatory risk tied to government pricing programs. The outcome could influence how other manufacturers handle similar disputes, though no immediate impact on Lilly’s broader operations has been cited in available sources.